Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
/in Dendritic Cells, International Publications, NSCLC /von 2024-02-10 / J Med Case Rep 2024 Feb;18(1):88Oncolytic virus-based combination therapy in breast cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2024-02-01 / Cancer Lett 2024 Mar;585:216634Glioblastoma vaccines: past, present, and opportunities
/in Dendritic Cells, Glioblastoma, International Publications /von 2024-01-05 / EBioMedicine 2024 Jan;100:104963Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
/in Breast Cancer, Dendritic Cells, International Publications /von 2023-12-26 / Mol Aspects Med 2024 Feb;95:101239Decoding immunogenic cell death from a dendritic cell perspective
/in Dendritic Cells, Immunogenic Cell Death, International Publications /von 2023-12-13 / Immunol Rev 2024 Jan;321(1):350-370Targeting immunogenic cell death for glioma immunotherapy
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications /von 2023-11-14 / Trends Cancer 2024 Jan;10(1):8-11Therapeutic cell-based vaccines for glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-11-12 / Med Oncol 2023 Nov;40(12):354Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
/in Dendritic Cells, International Publications, NSCLC /von 2023-11-06 / Cureus 2023 Nov;15(11):e48412The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de